Citarinostat is an investigational selective HDAC6 inhibitor under study for multiple myeloma and other haematological malignancies, designed to modulate protein homeostasis pathways with reduced pan-HDAC toxicity. Simson Pharma's Citarinostat reference standard supports early-stage analytical and research applications.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Citarinostat Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.